Reduction in prevalence | Number of cases averteda | Potential cost savingsb | Net benefits (costs AUD)c | Incremental cost-effectiveness ratio (ICER, AUD)d |
---|---|---|---|---|
Sensitivity 1: reduce value of saving high-risk youth to $1.673 M (base case $1.934 M) | ||||
2% | 22 | $42,548,000 | $3,048,000 | -$138,545 |
1% | 11 | $21,274,000 | -$18,226,000 | $1,656,909 |
Sensitivity 2: increase value of saving high-risk youth to $2.264 M (base case $1.934 M) | ||||
2% | 22 | $49,808,000 | $10,308,000 | -$468,545 |
1% | 11 | $24,904,000 | -$14,596,000 | -$1,326,909 |
Sensitivity 3: increase proportion of participants likely to embark on a high-risk pathway to 3% (base case 0.5%) | ||||
2% | 132 | $255,288,000 | -$215,788,000 | -$1,634,758 |
1% | 66 | $127,644,000 | -$88,144,000 | -$1,335,515 |